Stocktoria
TELA Bio, Inc. TELA
Nasdaq · stock · Surgical & Medical Instruments & Apparatus · website · IPO 2019-11-08
TELA Bio, Inc. financials (annual)
Bars are annual figures from 2018 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $80.3M | $69.3M | $58.5M | $41.4M | $29.5M | $18.2M | $15.4M | $8.3M |
| Gross profit | $54.3M | $46.5M | $40.1M | $27.0M | $18.8M | $11.2M | $9.3M | $2.9M |
| R&D expense | $9.2M | $8.8M | $9.6M | $8.9M | $6.7M | $4.3M | $4.2M | $4.3M |
| Operating income | -$33.8M | -$34.1M | -$44.1M | -$39.0M | -$29.5M | -$25.3M | -$19.2M | -$17.8M |
| Interest expense | — | — | $5.2M | $4.1M | $3.6M | $3.6M | $3.6M | $1.8M |
| Income tax | $230,000 | -$144,000 | — | — | — | — | — | — |
| Net income | -$38.8M | -$37.8M | -$46.7M | -$44.3M | -$33.3M | -$28.8M | -$22.4M | -$21.1M |
| EPS (diluted) | $-0.83 | $-1.33 | $-2.04 | $-2.72 | $-2.30 | $-2.23 | $-17.10 | — |
| Operating cash flow | -$28.2M | -$41.6M | -$40.9M | -$40.7M | -$30.4M | -$24.5M | -$25.5M | -$19.9M |
| Free cash flow | -$28.7M | -$42.6M | -$41.5M | -$41.6M | -$31.1M | -$24.6M | -$25.7M | -$20.0M |
| Cash & equivalents | $50.8M | $52.7M | $46.7M | $42.0M | $43.9M | $74.4M | $45.3M | $17.3M |
| Inventory | $11.0M | $12.8M | $13.2M | $11.8M | $7.7M | $3.9M | $4.6M | $4.3M |
| Total assets | $81.4M | $86.6M | $78.0M | $67.9M | $62.5M | $86.5M | $67.9M | $27.2M |
| Total liabilities | $75.1M | $58.1M | $59.2M | $53.5M | $42.4M | $37.4M | $37.0M | $40.9M |
| Shareholders' equity | $6.3M | $28.5M | $18.9M | $14.3M | $20.1M | $49.0M | $31.0M | -$137.9M |
Growth · year-over-year · Revenue CAGR 38.4%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue growth | +15.8% | +18.6% | +41.1% | +40.6% | +61.8% | +17.9% | +86.7% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.